For example, the clinical trial of BTX‐1188, a dual degrader targeting GSPT1 and IKZF1/3, was halted due to a business decision,[27] meanwhile the phase I/II clinical trial of CC‐90009 was terminated due to the lack of efficacy in the short‐term acute phase.[28] What we have learned from those clinical trials is that not all patients with different cancer types can respond to GSPT1 degraders, and the mechanisms behind the cancer biology of GSPT1 are still insufficient. The gene discussed is GSPT1; the disease is cancer.